About Apotex
Apotex is a publicly listed company based in Toronto (Canada) founded in 1974, and was acquired by SK Capital in September 2022. Generic pharmaceutical formulations are manufactured and exported by Apotex globally. The company has 13 employees. Apotex has completed 2 acquisitions, including Aveva and Searchlight Pharma. Its chief executive, as recorded, is Allan Oberman. Its website apotex.com draws about 60 thousand monthly visits. Its Indian entity Apotex Research Private Limited reported revenue of ₹727 Cr. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.
Company details
Apotex was founded in 1974 in Toronto, Canada, within the pharmaceutical sector. Generic formulations are produced by the company, with operations including research and development on both generic and innovative drugs. Products are distributed to every pharmacy in Canada and exported to various countries worldwide. Ferriprox has been approved for managing iron overload in patients with Thalassemia.
- Headquarters Toronto, Canada
- Employees 13
- Stage Acquired
- SectorsHealthcare
- Website category Health · Pharmacy
- Phone•••• ••••
- Website apotex.com
- Social LinkedIn Facebook
- Acquired by SK Capital (Sep 2022)
- Legal Name Apotex Health Corp.
- Indian entity revenue₹727 Cr
FY 2025 · +22% YoY
- Indian entity net profit₹76.62 Cr
FY 2025 · 11% margin
- Indian entity EBITDA₹149 Cr
FY 2025 · 21% margin
- Investors
- Employee Count13
- Investments & AcquisitionsAveva
& 1 more
- Acquired bySK Capital
(Sep 2022)
Associated legal entities of Apotex
Apotex operates through Apotex Research Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Apotex Research Private Limited CIN U73100KA2003PTC032103 | Active | 16 Jun 2003 | Jigani Hobli, Karnataka | ₹727 Cr | 1,236 | 5 | View details |
Investors in Apotex
Apotex has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include SK Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A global private investment firm focused on specialty sectors. | skcapitalpartners.com | New York, United States |
Investor details for Apotex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Apotex Research Private Limited (Apotex)
Apotex Research Private Limited is the primary company behind Apotex. The board of Apotex Research Private Limited currently have 4 directors; the longest-serving is Goutam Vilas Pujari, appointed in 2018. 15 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Goutam Vilas Pujari DIN 02891339 | Director | 01 Dec 2018 | 7 yrs 11 mo | Apotex Research Private Limited |
| Brian George Mcclelland DIN 06568789 | Director | 15 Sep 2023 | 3 yrs 2 mo | Apotex Research Private Limited |
| Rajesh Salwan DIN 07669286 | Additional Director | 18 Mar 2025 | 1 yr 8 mo | Apotex Research Private Limited |
| Uta Kellermann Renton DIN 10993254 | Additional Director | 18 Mar 2025 | 1 yr 8 mo | Apotex Research Private Limited |
People of Apotex
218 people are tracked at Apotex (102 in leadership, 116 in team); the tracked headcount is 13.
| Name | Role | Group |
|---|---|---|
Allan Oberman | CEO | Leadership |
Aditya Jaiswal | Director, Strategy & Analytics, Global Corporate Development | Leadership |
Saad Khanzada | Senior Director Of Finance | Leadership |
Joe Carrier | Senior Director Forecasting And Demand Planning | Leadership |
Melissa Bernard | Associate Director, Site Engineering | Leadership |
Kevin Mach | Associate Director, Capital Engineering - Leasehold Improvements, Laboratory, Research & Development | Leadership |
Amit B. | Deputy General Manager - Global Intellectual Property | Leadership |
Donald D'Anna | Vice President - Tax & Treasury | Leadership |
Art Tramonte | Vice President, Commercial Rest Of World | Leadership |
Daniel Johnson | Associate Director, Product Management & Commercial Operations | Leadership |
Rachel Floyd | Director, Senior Legal Counsel | Leadership |
Carlo Carinci | Global Director, Platform & Cloud Services | Leadership |
Jim Wheat | Vice President Product Supply Signet | Leadership |
Francesco Tallarico | Chief Legal Officer | Leadership |
Hector Rodriguez | Latam Finance Director | Leadership |
Olga Kalinina | Director, Global Intellectual Property And Legal Affairs | Leadership |
Lorena F. | Chief Information Officer | Leadership |
Miroslav Preradovic | Director, IT Services Management | Leadership |
Sadia Khan | Director, Corporate Finance | Leadership |
Sagiv Levi | Vice President, Head Of Global Transformation And OPEX | Leadership |
198 more people are available in the full profile.
Complete people profiles for Apotex
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Apotex
Apotex is a publicly listed company on the TSX with ticker symbol APTX in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date10 Jun 2026
- Listed onTSX: APTX
- Listed entityApotex Health Corp.
- Exchange sectorHealth technology
- ISINCA03772D1015
- Share price30.89 CAD (+0.32% on the day) · 2026-10-13
- Market capitalisation7,035,484,825.80 CAD
- Volume (last session)275,119
Financials of Apotex
Figures of Apotex Research Private Limited, the primary company behind Apotex, for FY 2025. Revenue was ₹727 Cr (+22% year on year). Net profit was ₹76.62 Cr (11% margin). EBITDA was ₹149 Cr (21% margin). Revenue has grown at a compounded annual rate of +10% over three years and +931% over five years.
- ₹727 CrRevenue · FY 2025 · +22% YoY
- ₹76.62 CrNet profit · 11% margin
- ₹149 CrEBITDA · 21% margin
- ₹292 CrPaid-up capital
- 1,236Employees (provident fund records)
- +10%Revenue CAGR, 3 years
- +931%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Apotex Research Private Limited are on its company page.
Detailed financial statements for Apotex
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Apotex
Apotex has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Aveva and Searchlight Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Specialty pharmaceuticals are acquired, developed, and commercialized by the company. | searchlightpharma.com | Montreal, Canada | 2015 | Apr 2024 | •••• | |
Drugs for multiple therapeutic areas are manufactured by Aveva. | avevadds.com | Miramar, United States | 2003 | Jun 2012 | •••• |
Complete acquisition details for Apotex
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Apotex
5 dated milestones of Apotex across 52 years, from founding to its latest funding, stage changes and deals.
- Founded Apotex is founded.
- Acquisition Acquires Aveva.
- Exit Acquired by SK Capital.
- Acquisition Acquires Searchlight Pharma.
- IPO Lists on the stock exchange (IPO).
Web traffic of Apotex
The website of Apotex (apotex.com) receives about 60.3K visits a month and ranks #457,120 among all websites worldwide, #847 in Pharmacy.
- Monthly visits60.3K
▼ 17% vs previous month
- Unique visitors30.5K
per month
- Global rank#457,120
among all websites
- Category rank#847
Health · Pharmacy
- Bounce rate44%
- Pages per visit2.5
- Average visit1 min 01 sec
- DevicesDesktop 38% · Mobile 62%
Websites whose visitors overlap most with Apotex. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pfizer.ca | 100% | #1,068,167 | View details | ||
astrazeneca.ca | astrazeneca.ca | 84% | #973,246 | – | |
| ycdscc.com | 81% | #1,322,015 | View details | ||
| carerx.ca | 80% | 46.7K | #724,974 | View details | |
| biovail.com | 79% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 27 similar websites and full traffic analytics for Apotex
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 27 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Apotex
Complete news archive for Apotex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Apotex
Apotex was founded in 1974.
Apotex is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Allan Oberman is the CEO of Apotex, as recorded in our data.
Apotex has 13 employees.
The primary company behind Apotex, Apotex Research Private Limited, reported revenue of ₹727 Cr for FY 2025, up 22% year on year.
Apotex was founded in 1974 in Toronto, Canada, within the pharmaceutical sector. Generic formulations are produced by the company, with operations including research and development on both generic and innovative drugs. Products are distributed to every pharmacy in Canada and exported to various countries worldwide. Ferriprox has been approved for managing iron overload in patients with Thalassemia.
Yes, Apotex is publicly traded on TSX under the ticker symbol APTX.
Apotex has made 2 acquisitions, including Aveva, and Searchlight Pharma.
Apotex has 1 investor. Key investors include SK Capital.
Apotex operates through Apotex Research Private Limited.
Yes. Apotex was acquired by SK Capital in September 2022.
The legal entities of Apotex currently have 5 directors, including Brian George Mcclelland, Rajesh Salwan, Goutam Vilas Pujari and others.

